Untitled

Neurohormones, Neurodevelopment, and Psychosis 281Muck-Seler, D., Pivac, N., Sagud, M., Jakovljevic, M., & Mihaljevic-Peles, A. (2002).The effects of paroxetine and tianeptine on peripheral biochemical markers in majordepression. Progress in Neuropsychopharmacology and Biological Psychiatry, 26,1235–1423.Neumann, C., & Walker, E. (1995). Developmental pathways to schizophrenia: Behavioralsubtypes. Journal of Abnormal Psychology, 104, 1–9.Ohl, F., Michaelis, T., Vollmann-Honsdorf, G. K., Kirschbaum, C., & Fuchs, E. (2000).Effect of chronic psychosocial stress and long-term cortisol treatment on hippocampus-mediatedmemory and hippocampal volume: a pilot-study in tree shrews. Psychoneuroendocrinology,25(4), 357–363.Pariante, C. M., Thomas, S. A., Lovestone, S., Makoff, A., & Kerwin, R. W. (2004). Doantidepressants regulate how cortisol affects the brain? Psychoneuroendocrinology, 29,423–447.Pfohl, B., Blum, N., & Zimmerman, M. (1997). Structured Interview for DSM-IV Personality(SIDP-IV). Washington, DC: American Psychiatric Press.Ritsner, M., Maayan, R., Gibel, A., Strous, R. D., Modai, I., & Weizman, A. (2004). Elevationof the cortisol/dehydroepiandrosterone ratio in schizophrenia patients. EuropeanNeuropsychopharmacology, 14(4), 267–273.Rodenbeck, A., Cohrs, S., Jordan, W., Huether, G., Ruther, E., & Hajak, G. (2003). Thesleep-improving effects of doxepin are paralleled by a normalized plasma cortisol secretionin primary insomnia: a placebo-controlled, double-blind, randomized, cross-overstudy followed by an open treatment over 3 weeks. Psychopharmacology, 170, 423–428.Ryan, M. C., Flanagan, S., Kinsella, U., Keeling, F., & Thakore, J. H. (2004). The effectsof atypical antipsychotics on visceral fat distribution in first episode, drug-naive patientswith schizophrenia. Life Science, 74, 1999–2008.Ryan, M. C. M., Collins, P., & Thakore, J. H. (2003). Impaired fasting glucose tolerancein first-episode, drug-naive patients with schizophrenia. American Journal of Psychiatry,160(2), 284–289.Ryan, M. C. M., Sharifi, N., Condren, R., & Thakore, J. H. (2004). Evidence of basalpituitary-adrenal overactivity in first episode, drug naive patients with schizophrenia.Psychoneuroendocrinology, 29(8), 1065–1070.Saitoh, O., Karns, C. M., & Courchesne, E. (2001). Development of the hippocampalformation from 2 to 42 years: MRI evidence of smaller area dentata in autism. Brain,124, 1317–1324.Sapolsky, R. M. (1994). Why zebras don’t get ulcers. New York: Friedman.Seidman, L. J., Pantelis, C., Keshavan, M. S., Faraone, S. V., Goldstein, J. M., Horton,N. J., Makris, N., Falkai, P., Caviness, V. S., & Tsuang, M. T. (2003). A review andnew report of medial temporal lobe dysfunction as a vulnerability indicator for schizophrenia:A magnetic resonance imaging morphometric family study of the parahippocampalgyrus. Schizophrenia Bulletin, 29(4), 803–830.Shenton, M. E., Dickey, C. C., Frumin, M., & McCarley, R. W. (2001). A review of MRIfindings in schizophrenia. Schizophrenia Research, 49(1–2), 1–52.Shirayama, Y., Hashimoto, K., Suzuki, Y., & Higuchi, T. (2002). Correlation of plasmaneurosteroid levels to the severity of negative symptoms in male patients with schizophrenia.Schizophrenia Research, 58(1), 69–74.Sonntag, A., Rothe, B., Guldner, J., Yassouridis, A., Holsboer, F., & Steiger, A. (1996).Trimipramine and imipramine exert different effects on the sleep EEG and on nocturnalhormone secretion during treatment of major depression. Depression, 4, 1–13.Sousa, N., & Almeida, O. F. (2002). Corticosteroids: sculptors of the hippocampal formation.Reviews in the Neurosciences, 13(1), 59–84.